Ledda
/
djledda-web

<html>
    <head><title></title></head>
    <body>
        <h1></h1>

        <p></p>
        <p>
            <strong>Heart and hormones &nbsp;</strong>&nbsp; The heart's unique behavior has given cardiologists a
            particularly mechanical perspective on biology. If a cardiologist and an oncologist have anything to talk
            about, it's likely to be about why cancer treatments cause heart failure; a cardiologist and an
            endocrinologist might share an interest in "cardioprotective estrogen" and "cardiotoxic obesity." Cell
            physiology and bioenergetics aren't likely to be their common interest. Each specialty has its close
            involvement with the pharmaceutical industry, shaping its thinking.
        </p>
        <p>
            <span>&nbsp;&nbsp; The drug industry has been lowering the numbers for cholesterol, blood pressure, and
                blood glucose that are considered to be the upper limit of normal, increasing the number of customers
                for their prescription drugs. Recently, publications have been claiming that the upper limit of the
                normal range of heart rates should be lower than 100 beats per minute; this would encourage doctors to
                prescribe more drugs to slow hearts, but the way the evidence is being presented, invoking the
                discredited "wear and tear" theory of aging, could have many unexpected harmful consequences. It would
                reinforce existing misconceptions about heart functions.&nbsp; &nbsp;</span>
            <span>&nbsp;&nbsp; A few decades ago, diuretics to lower blood pressure and digitalis/digoxin to increase
                the heart's strength of contraction were the main treatments for heart disease. In 1968, the annual
                number of deaths in the US from congestive heart failure (in which the heart beats more weakly, pumping
                less blood) was 10,000. By 1993 the number had increased to 42,000 per year. More recently, the annual
                number of deaths in which heart failure is the primary cause was more than 55,000. During these decades,
                many new drugs for treating heart disease were introduced, and the use of digoxin has decreased
                slightly. People with heart failure usually live with the condition for several years; at present about
                5.7 million people in the US live with heart failure. The prevalence of, and mortality from, other
                cardiovascular diseases (such as hypertension and abnormalities of the coronary arteries) are higher,
                but congestive heart failure is especially important to understand, because it involves defective
                function of the heart muscle itself.</span>
            <span>&nbsp;&nbsp;&nbsp; Although Albert Szent-Gyorgyi is known mostly for his discovery of vitamin C and
                his contribution to understanding the tricarboxylic acid or Krebs cycle, his main interest was in
                understanding the nature of life itself, and he focused mainly on muscle contraction and cancer growth
                regulation. In one of his experiments, he compared the effects of estrogen and progesterone on rabbit
                hearts. A basic property of the heart muscle is that when it beats more frequently, it beats more
                strongly. This is called the staircase effect, from the way a tracing of its motion rises, beat by beat,
                as the rate of stimulation is increased. This is a logical way to behave, but sometimes it fails to
                occur: In shock, and in heart failure, the pulse rate increases, without increasing the volume of blood
                pumped in each contraction.</span>
            <span>&nbsp;&nbsp; Szent-Gyorgyi found that estrogen treatment decreased the staircase effect, while
                progesterone treatment increased the staircase. He described the staircase as a situation in which
                function (the rate of contraction) builds structure (the size of the contraction). Progesterone allowed
                "structure" to be built by the contraction, and estrogen prevented that.</span>
            <span>(It's interesting to compare these effects of the hormones to the more general idea of anabolic and
                catabolic hormones, in which more permanent structures in cells are affected.)</span>
            <span>&nbsp;&nbsp; The rapid and extensive alternation of contraction and relaxation made possible by
                progesterone is also produced by testosterone (Tsang, et al., 2009). Things that increase the force of
                contraction are called inotropic, and the things that promote relaxation are called lusitropic;
                progesterone and testosterone are both positively inotropic and lusitropic, improving contraction and
                relaxation. Estrogen is a negative lusitropic hormone (Filice, et al., 2011), and also a negative
                inotropic hormone (Sitzler, et al., 1996), that is, it impairs both relaxation and
                contraction.&nbsp;</span>
            <span>&nbsp;&nbsp; Another standard term describing heart function is chronotropy, referring to the
                frequency of contraction. Because of the staircase interaction of frequency and force, there has been
                some confusion in classifying drugs according to chronotropism. In a state of shock or estrogen
                dominance, an inotropic drug will slow the heart rate by increasing the amount of blood pumped. This
                relationship caused digitalis' effect to be thought of as primarily slowing the rate of contraction
                (Willins and Keys, 1941), though its main effect is positively inotropic. It was traditionally used to
                treat edema, by stimulating diuresis, which is largely the result of its inotropic action. Progesterone
                and testosterone's inotropic action can also slow the heart beat by strengthening it.</span>
            <span>&nbsp;&nbsp; I think it was a little before Szent-Gyorgyi's heart experiment that Hans Selye had
                discovered that a large dose of estrogen created a shock-like state. Shock and stress cause estrogen to
                increase, and decrease progesterone and testosterone.</span>
            <span>&nbsp;&nbsp; About 30 years after Szent-Gyorgyi's work, people began to realize that digoxin and other
                heart stimulating molecules can be found in animals and humans, as metabolites of progesterone and
                possibly DHEA (Somogyi, et al., 2004).&nbsp;</span>
            <span>&nbsp;&nbsp; The regulatory proteins that are involved in estrogen's negative lusi- and inotropic
                actions (decreasing pumping action) have been known for over 20 years to be regulated by the thyroid
                hormone to produce positive lusi- and inotropic actions on the heart (increasing its pumping action),
                and thyroid's beneficial effects on heart and skeletal muscle have been known empirically for 100 years.
                However, drug centered cardiologists, reviewing the currently available drugs approved by the FDA, have
                typically concluded that "drugs targeted to achieve these objectives are not available" (Chatterjee,
                2002).</span>
            <span>&nbsp;&nbsp;&nbsp; When a muscle or nerve is fatigued, it swells, retaining water. When the swelling
                is extreme, its ability to contract is limited. Excess water content resembles a partly excited state,
                in which increased amounts of sodium and calcium are free in the cytoplasm. Energy is needed to
                eliminate the sodium and calcium, or to bind calcium, allowing the cell to extrude excess water and
                return to the resting state. Thyroid hormone allows cells' mitochondria to efficiently produce energy,
                and it also regulates the synthesis of the proteins (phospholamban and calcisequestrin) that control the
                binding of calcium. When the cell is energized, by the mitochondria working with thyroid, oxygen, and
                sugar, these proteins rapidly change their form, binding calcium and removing it from the contractile
                system, allowing the cell to relax, to be fully prepared for the next contraction. If the calcium isn't
                fully and quickly bound, the cell retains extra water and sodium, and isn't able to fully relax.</span>
            <span>&nbsp;&nbsp; Heart failure is described as "diastolic failure" when the muscle isn't able to fully
                relax. In an early stage, this is just a waterlogged (Iseri, et al., 1952), fatigued condition, but when
                continued, the metabolic changes lead to fibrosis and even to calcification of the heart muscle.</span>
            <span>&nbsp;&nbsp; Many children approaching puberty, as estrogen is increasing and interfering with thyroid
                function, have "growing pains," in which muscles become tense and sore after prolonged activity. When
                hypothyroidism is severe, it can cause myopathy, in which the painful swollen condition involves the
                leakage of muscle proteins (especially myoglobin) into the blood stream, allowing it to be diagnosed by
                a blood test. The combination of hypothyroidism with fatigue and stress can lead to the breakdown and
                death of muscle cells, rhabdomyolysis.&nbsp;</span>
            <span>&nbsp;&nbsp; The blood lipid lowering drugs, statins and fibrates, impair mitochondrial respiration
                (Satoh, et al., 1995, 1994; Brunmair, et al., 2004), and increase the incidence of rhabdomyolysis
                (Barker, et al., 2003; Wu, et al., 2009; Fallah, et al., 2013). Interference with coenzyme Q10 is not
                the only mechanism by which they can cause myopathy (Nakahara, et al., 1998). The harmful effect of
                lowering cholesterol seems to be relevant to heart failure: "In light of the association between high
                cholesterol levels and improved survival in HF, statin or other lipid-lowering therapy in HF remains
                controversial (Horwich, 2009).</span>
            <span>&nbsp;&nbsp; Heart muscle and skeletal muscle are similar in their structural responses to
                interference with mitochondrial functions, namely, swelling, reduced contractile ability, and
                dissolution. When myoglobin has been found in the blood and urine, it has been assumed to come from
                skeletal muscles, but the heart's myoglobin has been found to be depleted in a patient with
                myoglobinuria (Lewin and Moscarello, 1966). When heart failure is known to exist, similar changes can be
                found in the skeletal muscles (van der Ent, et al., 1998).</span>
            <span>&nbsp;&nbsp; Stress, in the form of pressure-overload (Zhabyeyev, et al., 2013), or overactivity of
                the renin-angiotensin system (Mori, et al., 2013) and sympathetic nervous system or adrenergic chemicals
                (Mori, et al., 2012), or a failure of energy caused by diabetes, insulin deficiency, or hypothyroidism,
                causes a shift of energy production from the oxidation of glucose to the oxidation of fatty acids, with
                the release, rather than oxidation, of the lactic acid produced from glucose. This sequence, from
                reduced efficiency of energy production to heart failure, can be opposed by agents that reduce the
                availability of fatty acids and promote the oxidation of glucose. Niacinamide inhibits the release of
                free fatty acids from the tissues, and thyroid sustains the oxidation of glucose. This principle is now
                widely recognized, and the FDA has approved a drug that inhibits the oxidation of fatty acids
                (raloxazine, 2006), but which has serious side effects. Glucose oxidation apparently is necessary for
                preventing the intracellular accumulation of free calcium and fatty acids (Jeremy, et al., 1992; Burton,
                et al., 1986; Ivanics, et al., 2001). The calcium binding protein which is activated by thyroid and
                inhibited by estrogen seems to be activated by glucose and inhibited by fatty acids (Zarain-Herzberg and
                Rupp, 1999).&nbsp;</span>
            <span>&nbsp;&nbsp; Diabetes or fasting increases free fatty acids, and forces cells to shift from oxidation
                of glucose to oxidation of fatty acids, inhibiting the binding of calcium (McKnight, et al., 1999).
                Providing a small amount of sugar (0.8% sucrose in their drinking water) restored the calcium binding
                and heart function, without increasing either thyroid hormone or insulin (Rupp, et al., 1988, 1999,
                1994). Serum glucose was lowered, as the ability to oxidize sugar was restored by lowering free fatty
                acids. Activity of the sympathetic nervous system is lowered as efficiency is increased.&nbsp;</span>
            <span>&nbsp;&nbsp; Digoxin stimulates mitochondrial energy production in skeletal and heart muscle
                (Tsyganil, et al., 1982), increasing the oxidation of glucose, rather than fatty acids, supporting the
                effect of thyroid hormone. The statins have the opposite effect, decreasing the oxidation of
                glucose.&nbsp;</span>
            <span>&nbsp;&nbsp; One of estrogen's effects is to chronically increase the circulation of free fatty acids,
                and to favor the long chain polyunsaturated fatty acids, such as EPA and DHA. These fatty acids, which
                slow the heart rate (Kang and Leaf, 1994), extend the excited state (action potential: Li, et al.,
                2011), and are negatively inotropic (Dhein, et al., 2005; Macleod, et al., 1998; Negretti, et al.,
                2000), are being proposed as heart protective drugs. (EPA and alpha-linoleic acid also prolong the QT
                interval: Dhein, et al., 2005).&nbsp;</span>
            <span>&nbsp;&nbsp; Many publications still promote estrogen as a cardioprotective drug, but there is now
                increased recognition of its role in heart failure and sudden cardiac death. A prolonged excited state
                (action potential) and delayed relaxation (QT interval) are known to increase the risk of arrhythmia and
                sudden death, and estrogen, which causes those changes in humans, causes sudden cardiac death in
                susceptible rabbits, with an adrenergic stimulant increasing the arrhythmias, and progesterone and
                androgen preventing them (Odening et al., 2012). Progesterone's protective effect seems to be the result
                of accelerating recovery of the resting state (Cheng, et al., 2012).&nbsp;</span>
            <span>&nbsp;&nbsp; Estrogen's interactions with adrenalin in promoting blood vessel constriction has been
                known for many years (for example, Cheng and Gruetter, 1992). Progesterone blocks that effect of
                estrogen (Moura and Marcondes, 2001). Environmental estrogens such as BPA can exacerbate ventricular
                arrhythmia caused by estrogen (Yan, et al., 2013). The hearts of mice genetically engineered to lack
                aromatase, the enzyme that synthesizes estrogen, were more resistant to damage by being deprived of
                blood for 25 minutes (Bell, et al., 2011), leading the authors to suggest that aromatase inhibition
                might be helpful for heart disease.&nbsp;</span>
            <span>&nbsp;&nbsp; In the stressed, energy depleted failing heart, muscle cells die and are replaced by
                connective tissue cells. The growth produced by over-exposure to adrenergic stimulation leads to
                stiffening and reduced functioning. However, under the influence of thyroid hormone a high work load
                leads to functional enlargement, which simply increases the pumping ability. Because of the traditional
                belief that heart cells can't replicate, this functional growth was believed to be produced purely by
                the enlargement of cells, but in recent years the existence of stem cells able to create new heart
                muscle has been recognized. Thyroid is likely to be one of the hormones responsible for allowing stem
                cells to differentiate into cardiomyocytes.</span>
            <span>&nbsp;&nbsp; In this context, of cellular differentiation as a life-long process, we can see the
                changes of a failing heart as a differentiation which is forced to take an inappropriate course. The
                calcification of blood vessels caused by phosphate excess and vitamin K deficiency involves the
                expression of a protein which has its proper place in the skeleton. The replacement of heart muscle by
                fibrous connective tissue and even bone is a basic biological problem of differentiation, and the
                responsible factors--stress, increased estrogen, deficient thyroid hormone, suppression of glucose
                oxidation by fatty acids, etc.--are involved in the problems of differentiation that occur in other
                degenerative processes, such as sarcopenia, dementia, and cancer.</span>
            <span>&nbsp;&nbsp; There have been arguments about the nature of wound healing and regeneration, regarding
                the origin of the new cells--whether they are from the dedifferentiation of local cells, or the
                migration of stem cells. The evidence is that both can occur, depending on the tissue and the situation.
                The deterioration of an organ is probably not a question of a lack of stem cells, but of changed
                conditions causing them to differentiate into something inappropriate for the full functioning of that
                organ.&nbsp;</span>
            <span>&nbsp;&nbsp; Various stresses can cause cells to dedifferentiate, but hypoxia is probably a common
                denominator. In the absence of estrogen, hypoxia can activate the "estrogen receptor."&nbsp; Estrogen is
                in some situations a hormone of dedifferentiation, facilitating the formation of new cells in stressed
                tissues, as aromatase is induced. However, the presence of polyunsaturated fats, tending to increase in
                concentration with age, causes the processes of renewal to produce exaggerated inflammation, with
                prostaglandins participating in the processes of development and differentiation. Estrogen, by
                increasing the concentration of free fatty acids, especially polyunsaturated fatty acids, contributes to
                the metabolic shift away from glucose oxidation, toward the formation of lactic acid, and away from the
                full organ-specific differentiation.</span>
            <span>&nbsp;&nbsp; This perspective puts heart failure, cancer, and the other degenerative diseases onto the
                same biological basis, and shows why certain conditions and therapies can be appropriate for all of
                them.</span>
            <span>&nbsp;&nbsp; Problems that seem relatively trivial become more meaningful when they are seen in terms
                of these mechanisms. Some problems that become very common by middle age are "palpitations," orthostatic
                hypotension, orthostatic tachycardia, and varicose veins. The negative inotropic effect of estrogen in
                the heart has a parallel in the smooth muscle of veins, in which the muscles are weakened, and their
                distensibility increased, when estrogen isn't sufficiently opposed by progesterone. This allows the
                veins in the lower part of the body to be distended abnormally when standing, reducing the amount of
                blood returning to the heart, so that the volume pumped with each stroke is small, requiring faster
                beating. The reduced blood volume reaching the brain can cause fainting. When it becomes chronic, it can
                lead to the progressive distortion of the veins. An excess of estrogen is associated with varicose veins
                in men, as well as women. (Raj, 2006; Ciardullo, et al., 2000; Kendler, et al., 2009; Asciutto, et al.,
                2010; Raffetto, et al., 2010).</span>
            <span>&nbsp;&nbsp; The simplicity of things such as supplementing thyroid, progesterone, and sugar, avoiding
                an excess of phosphate in relation to calcium, and avoiding polyunsaturated fats, makes it possible for
                people to take action themselves, without having to depend on the medical system. Most physicians still
                warn their patients of the dangers of thyroid supplements, especially the active T3 hormone, for their
                heart, but in at least one specialty, its value is recognized. Heart transplant surgeons have discovered
                that administering T3 to the brain-dead heart donor before removing the heart improves its viability and
                function in the recipient (Novitzky, 1996). Around this time, the manufacturers of Cytomel conceived the
                idea of marketing it as a "heart drug," which would make it much more profitable.</span>
            <span>&nbsp;&nbsp; Another technique that is easy to use to lower blood pressure and improve heart rhythm is
                to breathe into a paper bag for a minute or two at a time, to increase the carbon dioxide content of the
                blood. This has a vasodilating effect, reducing the force required to circulate the blood, and reduces
                anxiety. Rhubarb and emodin (a chemical found in rhubarb and cascara) have been found to have heart
                protective actions. A considerable amount of research showed that vitamin K is effective for treating
                hypertension, but again, most doctors warn against its use, because of its reputation as a clot forming
                vitamin. Recently, the value of the "blood thinner" warfarin, a vitamin K antagonist, has been
                questioned for people with heart failure (An, et al., 2013; Lee, et al., 2013). There have been several
                recent warnings about the production of arrhythmia by drugs that increase serotonin's effects (e.g.,
                Stillman, et al., 2013).</span>
            <span>&nbsp;&nbsp;&nbsp; Measuring the speed of relaxation of the Achilles tendon reflex twitch is a
                traditional method for judging thyroid function, because in hypothyroidism the relaxation is visibly
                delayed. This same retardation can be seen in the electrocardiogram, as a prolonged QT interval, which
                is associated with arrhythmia and sudden death. Insomnia, mania, and asthma are other conditions in
                which defective relaxation is seen, under the influence of low thyroid function, and an insufficiently
                opposed influence of estrogen.</span>
            <span><h3>REFERENCES</h3></span>
            <span>J Pathol. 2000 Aug;191(4):434-42. Expression of nitric oxide synthase isoforms and arginase in normal
                human skin and chronic venous leg ulcers. Abd-El-Aleem SA, Ferguson MW, Appleton I, Kairsingh S, Jude
                EB, Jones K, McCollum CN, Ireland GW.</span>
            <span>PLoS One. 2013;8(4):e57661. The occurrence of warfarin-related nephropathy and effects on renal and
                patient outcomes in korean patients. An JN, Ahn SY, Yoon CH, Youn TJ, Han MK, Kim S, Chin HJ, Na KY,
                Chae DW.</span>
            <span>Eur J Vasc Endovasc Surg. 2010 Jul;40(1):117-21. Oestradiol levels in varicose vein blood of patients
                with and without pelvic vein incompetence (PVI): diagnostic implications. Asciutto G, Mumme A, Asciutto
                KC, Geier B.</span>
            <span>Diabetes Care August 2003 vol. 26 no. 8 2482-2483. Fenofibrate Monotherapy Induced Rhabdomyolysis.
                Barker BJ, Goodenough RR, Falko JM.</span>
            <span>Endocrinology. 2011 Dec;152(12):4937-47. Aromatase deficiency confers paradoxical postischemic
                cardioprotection. Bell JR, Mellor KM, Wollermann AC, Ip WT, Reichelt ME, Meachem SJ, Simpson ER,
                Delbridge LM.</span>
            <span>J Pharmacol Exp Ther. 2004 Oct;311(1):109-14. Fenofibrate impairs rat mitochondrial function by
                inhibition of respiratory complex I. Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H,
                Waldhäusl W, Fürnsinn C.</span>
            <span>Am J Geriatr Cardiol. 2002;11(3). Primary Diastolic Heart Failure, Chatterjee K.</span>
            <span>Eur J Pharmacol. 1992 May 14;215(2-3):171-6. Chronic estrogen alters contractile responsiveness to
                angiotensin II and norepinephrine in female rat aorta. Cheng DY, Gruetter CA.</span>
            <span>Eur J Pharmacol. 2012 Aug 15;689(1-3):172-8. Frequency-dependent acceleration of cardiac
                repolarization by progesterone underlying its cardiac protection against drug-induced proarrhythmic
                effects in female rabbits. Cheng J, Zhang J, Ma X, Su D.</span>
            <span>J Vasc Surg. 2000 Sep;32(3):544-9. High endogenous estradiol is associated with increased venous
                distensibility and clinical evidence of varicose veins in menopausal women. Ciardullo AV, Panico S,
                Bellati C, Rubba P, Rinaldi S, Iannuzzi A, Cioffi V, Iannuzzo G, Berrino F.</span>
            <span>&nbsp;Naunyn Schmiedebergs Arch Pharmacol. 2005 Mar;371(3):202-11. Antiarrhythmic and
                electrophysiological effects of long-chain omega-3 polyunsaturated fatty acids. Dhein S, Michaelis B,
                Mohr FW. "All compounds exhibited a negative inotropic and chronotropic effect."</span>
            <span>Australas Med J. 2013 Mar 31;6(3):112-4. Life-threatening rhabdomyolysis following the interaction of
                two commonly prescribed medications. Fallah A, Deep M, Smallwood D, Hughes P.</span>
            <span>Curr Atheroscler Rep. 2009 Sep;11(5):343-9. Low-density lipoprotein in the setting of congestive heart
                failure: is lower really better? Horwich T.</span>
            <span>Am Heart J. 1952 Feb;43(2):215-27. Water and electrolyte content of cardiac and skeletal muscle in
                heart failure and myocardial infarction. ISERI LT, ALEXANDER LC, McCAUGHEY RS, BOYLE AJ, MYERS GB.</span
            >
            <span>Mol Cell Biochem. 2001 Oct;226(1-2):119-28. Concomitant accumulation of intracellular free calcium and
                arachidonic acid in the ischemic-reperfused rat heart. Ivanics T, Miklós Z, Dézsi L, Ikrényi K, Tóth A,
                Roemen TH, Van der Vusse GJ, Ligeti L.</span>
            <span>Circ Res. 1992 Jun;70(6):1180-90. Relation between glycolysis and calcium homeostasis in postischemic
                myocardium. Jeremy RW, Koretsune Y, Marban E, Becker LC.</span>
            <span>&nbsp;Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9886-90. Effects of long-chain polyunsaturated
                fatty acids on the contraction of neonatal rat cardiac myocytes. Kang JX, Leaf A.</span>
            <span>&nbsp;</span>
            <span>Angiology. 2009 Jun-Jul;60(3):283-9. Elevated serum estradiol/testosterone ratio in men with primary
                varicose veins compared with a healthy control group. Kendler M, Blendinger Ch, Haas E.</span>
            <span>Circ Heart Fail. 2013 Mar;6(2):287-92. Risk-benefit profile of warfarin versus aspirin in patients
                with heart failure and sinus rhythm: a meta-analysis. Lee M, Saver JL, Hong KS, Wu HC, Ovbiagele
                B.</span>
            <span>Can Med Assoc J. 1966 Jan 15;94(3):129-31. Cardiac myoglobin in myoglobinuria.</span>
            <span>Lewin PK, Moscarello MA.</span>
            <span>Lipids. 2011 Feb;46(2):163-70. Increasing DHA and EPA concentrations prolong action potential
                durations and reduce transient outward potassium currents in rat ventricular myocytes. Li HX, Wang RX,
                Li XR, Guo T, Wu Y, Guo SX, Sun LP, Yang ZY, Yang XJ, Jiang WP.</span>
            <span>J Appl Physiol. 1999 Nov;87(5):1909-13. Biphasic changes in heart performance with food restriction in
                rats. McKnight KA, Rupp H, Dhalla KS, Beamish RE, Dhalla NS.</span>
            <span>Eur J Pharmacol. 1998 Sep 4;356(2-3):261-70. The electrical and mechanical response of adult guinea
                pig and rat ventricular myocytes to omega3 polyunsaturated fatty acids. Macleod JC, Macknight AD,
                Rodrigo GC.</span>
            <span>Circulation: Heart Failure. 2012; 5: 493-503. Agonist-Induced Hypertrophy and Diastolic Dysfunction
                Are Associated With Selective Reduction in Glucose Oxidation. A Metabolic Contribution to Heart Failure
                With Normal Ejection Fraction. Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, Wagg CS, Kassiri Z,
                Lopaschuk GD, Oudit GY.</span>
            <span>Life Sci. 2001 Jan 12;68(8):881-8. Influence of estradiol and progesterone on the sensitivity of rat
                thoracic aorta to noradrenaline. Moura MJ, Marcondes FK.</span>
            <span>Toxicol Appl Pharmacol. 1998 Sep;152(1):99-106. Myopathy induced by HMG-CoA reductase inhibitors in
                rabbits: a pathological, electrophysiological, and biochemical study. Nakahara K, Kuriyama M, Sonoda Y,
                Yoshidome H, Nakagawa H, Fujiyama J, Higuchi I, Osame M.</span>
            <span>J Physiol. 2000 Mar 1;523 Pt 2:367-75. Inhibition of sarcoplasmic reticulum function by
                polyunsaturated fatty acids in intact, isolated myocytes from rat ventricular muscle.</span>
            <span>Negretti N, Perez MR, Walker D, O'Neill SC.</span>
            <span>Thyroid 1996 Oct;6(5):531-6. Novel actions of thyroid hormone: the role of</span>
            <span>triiodothyronine in cardiac transplantation. Novitzky D</span>
            <span>Heart Rhythm. 2012 May;9(5):823-32. Estradiol promotes sudden cardiac death in transgenic long QT type
                2 rabbits while progesterone is protective. Odening KE, Choi BR, Liu GX, Hartmann K, Ziv O, Chaves L,
                Schofield L, Centracchio J, Zehender M, Peng X, Brunner M, Koren G.</span>
            <span>J Vasc Surg. 2010 Apr;51(4):972-81. Estrogen receptor-mediated enhancement of venous relaxation in
                female rat: implications in sex-related differences in varicose veins. Raffetto JD, Qiao X, Beauregard
                KG, Khalil RA.</span>
            <span>Indian Pacing Electrophysiol. J. 2006;6(2):84-99.The Postural Tachycardia Syndrome (POTS):
                Pathophysiology, Diagnosis &amp; Management. Raj SR</span>
            <span>Mol Cell Biochem. 1994 Mar 16;132(1):69-80. Modification of myosin isozymes and SR Ca(2+)-pump ATPase
                of the diabetic rat heart by lipid-lowering interventions. Rupp H, Elimban V, Dhalla NS.</span>
            <span>Biochem Biophys Res Commun. 1989 Oct 16;164(1):319-25. Diabetes-like action of intermittent fasting on
                sarcoplasmic reticulum Ca2+-pump ATPase and myosin isoenzymes can be prevented by sucrose. Rupp H,
                Elimban V, Dhalla NS.</span>
            <span>Biochem Biophys Res Commun. 1988 Oct 31;156(2):917-23. Sucrose feeding prevents changes in myosin
                isoenzymes and sarcoplasmic reticulum Ca2+-pump ATPase in pressure-loaded rat heart. Rupp H, Elimban V,
                Dhalla NS.</span>
            <span>&nbsp;Br J Pharmacol. 1995 Sep;116(2):1894-8. Effects of 3-hydroxy-3-methylglutaryl coenzyme A
                reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.</span>
            <span>Satoh K, Yamato A, Nakai T, Hoshi K, Ichihara K.</span>
            <span>&nbsp;Eur J Pharmacol. 1994 Aug 3;270(4):365-9. Influence of 3-hydroxy-3-methylglutaryl coenzyme A
                reductase inhibitors on mitochondrial respiration in rat liver during ischemia. Satoh K, Nakai T,
                Ichihara K.</span>
            <span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</span>
            <span>Br J Pharmacol. 1997 Oct;122(4):772-8. Imbalance between the endothelial cell-derived contracting
                factors prostacyclin and angiotensin II and nitric oxide/cyclic GMP in human primary varicosis.
                Schuller-Petrovic S, Siedler S, Kern T, Meinhart J, Schmidt K, Brunner F.</span>
            <span>J Clin Invest. 1996 Nov 15;98(10):2244-50. Glucose plus insulin regulate fat oxidation by controlling
                the rate of fatty acid entry into the mitochondria. Sidossis LS, Stuart CA, Shulman GI, Lopaschuk GD,
                Wolfe RR.</span>
            <span>Orv Hetil. 2004 Feb 8;145(6):259-66. [New steroid hormone family: endogenous cardiac glycosides and
                their role in physiologic and pathologic conditions]. [Article in Hungarian] Somogyi J, Szalay J,
                Pándics T, Rosta K, Csermely P, Vér A.</span>
            <span>Headache. 2013 Jan;53(1):217-24. QT prolongation, Torsade de Pointes, myocardial ischemia from
                coronary vasospasm, and headache medications. Part 2: review of headache medications, drug-drug
                interactions, QTc prolongation, and other arrhythmias. Stillman MJ, Tepper DE, Tepper SJ, Cho L.</span>
            <span>Am J Physiol Cell Physiol. 2009 Apr;296(4):C766-82. Testosterone-augmented contractile responses to
                alpha1- and beta1-adrenoceptor stimulation are associated with increased activities of RyR, SERCA, and
                NCX in the heart. Tsang S, Wong SS, Wu S, Kravtsov GM, Wong TM.</span>
            <span>Farmakol Toksikol. 1982 Jan-Feb;45(1):30-2. [Effect of digoxin, strophanthin and isolanid on oxygen
                absorption, oxidative phosphorylation and the amount of cytochromes in the myocardial mitochondria and
                their ATPase activity]. Tsyganiĭ AA, Medvinskaia NA, Rudenko AF.</span>
            <span>Eur Heart J. 1998 Jan;19(1):124-31. A non-invasive selective assessment of type I fibre mitochondrial
                function using&nbsp; 31P NMR spectroscopy. Evidence for impaired oxidative phosphorylation rate in
                skeletal muscle in patients with chronic heart failure. van der Ent M, Jeneson JA, Remme WJ, Berger R,
                Ciampricotti R, Visser F.</span>
            <span>Withering W. An account of the foxglove and some of its medical uses, with practical remarks on
                dropsy, and other diseases. In Willins FA, Keys TE, eds. Classics of Cardiology. Volume I. New York, NY:
                Henry Schuman, Dover Publications; 1941: 231–252.</span>
            <span>Eur J Clin Pharmacol. 2009 Dec;65(12):1169-74. Rhabdomyolysis associated with fibrate therapy: review
                of 76 published cases and a new case report. Wu J, Song Y, Li H, Chen J.</span>
            <span>Cardiovasc Res (2013) 97 (4): 676-685. Pressure-overload-induced heart failure induces a selective
                reduction in glucose oxidation at physiological afterload. Zhabyeyev P, Gandhi M, Mori J, Basu R.,
                Kassiri Z, Clanachan A., Lopaschuk GD, Oudit GY.</span>
        </p>

        © Ray Peat Ph.D. 2015. All Rights Reserved. www.RayPeat.com
    </body>
</html>